USA flag logo/image

An Official Website of the United States Government

Development of a discovery platform based on microfluidics and fluorescent cell…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2011 / SBIR
Agency Tracking Number:
R43DK092122
Solicitation Year:
2011
Solicitation Topic Code:
NIDDK
Solicitation Number:
PA08-114
Small Business Information
NIVARTA, INC.
One Broadway 14th Floor Cambridge, MA 02142
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2011
Title: Development of a discovery platform based on microfluidics and fluorescent cell f
Agency: HHS
Contract: 1R43DK092122-01
Award Amount: $695,816.00
 

Abstract:

DESCRIPTION (provided by applicant): The overall goal of the project is to develop discovery platform based on microfluidics and functional cell assays that is suitable for screening hundreds of proteins or small-molecule compounds simultaneously in a cost-effective and high throughput manner. The projects Specific Aims are: (1) To develop a microfluidic-based platform for high-throughput screening of potential protein and small molecule therapeutics. (2) To develop an insulin stimulated glucose uptake assay in differentiated 3T3-L1 adipocytes using fluorescent 2-deoxy glucose (2-DOG) analog. (3) To integrate and perform a functional 2-DOG uptake assay in the microfluidics based multi-well cell culture biochip. The deliverable from this completed project isa cost-effective microfluidics based platform suitable for high throughput screening of proteins and small molecule therapeutic compounds. PUBLIC HEALTH RELEVANCE: The long term objective of the project is to identify protein and small molecule therapeutics to treat diseases such as diabetes, obesity, cancer and neurological disorders. As a first step towards this objective, a platform based on microfluidics technology and functional cell bioassays is being developed to screen the entire human proteome and small molecule libraries in a cost-effective and time saving manner. Presently, safety and efficacy of most of the drugs in the market is still a primary concern. However, with more therapies becoming available, it is possible that not only safety standards will be met but also the cost of drugs will be lowered.

Principal Investigator:

Muralikrishna Vemula
617-871-9782
mvemula@nivarta.com

Business Contact:

Muralikrishna Vemula
617-871-9782
mvemula@nivarta.com
Small Business Information at Submission:

NIVARTA, INC.
One Broadway 14th Floor Cambridge, MA 02142

EIN/Tax ID: 127119475
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No